gemfibrozil has been researched along with ciprofibrate in 40 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (10.00) | 18.7374 |
1990's | 15 (37.50) | 18.2507 |
2000's | 15 (37.50) | 29.6817 |
2010's | 6 (15.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Frishman, WH; Kahn, S; Zimetbaum, P | 1 |
Feller, DR; Kocarek, TA | 1 |
Krause, BR; Newton, RS | 1 |
Hunninghake, DB; Peters, JR | 1 |
Eacho, PI; Foxworthy, PS | 1 |
Baldwin, LA; Calabrese, EJ; Donohue, M; Kostecki, PT; Leonard, DA | 1 |
Schonfeld, G | 1 |
Dujovne, CA; Lozada, A | 1 |
Shepherd, J | 1 |
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM | 1 |
de Valois, JC; Kastelein, JJ; Knipscheer, HC; van den Ende, B; Wouter ten Cate, J | 1 |
de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC | 1 |
Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
de Maat, MP; Kastelein, JJ; Kluft, C; Knipscheer, HC; Kockx, M; Kooistra, T; Princen, HM | 1 |
Bruckert, E | 1 |
Kockx, M; Kooistra, T; Princen, HM | 1 |
Wallace, KB; Zhou, S | 1 |
Abramowicz, D; Antoine, M; Broeders, N; Knoop, C; Tielemans, C | 1 |
Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
Elisaf, M; Kakafika, A; Tsimihodimos, V | 1 |
Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L | 1 |
Jagroon, IA; Mikhailidis, DP | 1 |
Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
Athyros, V; Bairaktari, E; Elisaf, M; Ganotakis, E; Rizos, E; Seferiades, C; Tsimihodimos, V | 1 |
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
Hauzer, A; Komsta, Ł; Majchrzak, E; Misztal, G | 1 |
Berneis, K; Rizzo, M | 1 |
7 review(s) available for gemfibrozil and ciprofibrate
Article | Year |
---|---|
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides | 1991 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids | 1987 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL | 1993 |
[Treatment of familial combined hyperlipidemia].
Topics: Clinical Protocols; Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Nicotinic Acids; Simvastatin | 1997 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Treatment Outcome | 2007 |
8 trial(s) available for gemfibrozil and ciprofibrate
Article | Year |
---|---|
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Retrospective Studies | 1996 |
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Smoking; Tissue Plasminogen Activator; Treatment Outcome | 1997 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diet; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 2001 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
25 other study(ies) available for gemfibrozil and ciprofibrate
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Quantitative assessment of enzyme induction by peroxisome proliferators and application to determination of effects on triglyceride biosynthesis in primary cultures of rat hepatocytes.
Topics: Acyl-CoA Oxidase; Animals; Cells, Cultured; Clofibrate; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Fibric Acids; Gemfibrozil; Kinetics; Liver; Microbodies; Mixed Function Oxygenases; Oxidoreductases; Rats; Triglycerides | 1989 |
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates | 1986 |
Conditions influencing the induction of peroxisomal beta-oxidation in cultured rat hepatocytes.
Topics: Animals; Bezafibrate; Catalase; Cell Survival; Clofibric Acid; Fibric Acids; Gemfibrozil; In Vitro Techniques; Liver; Male; Microbodies; Pentanoic Acids; Rats; Rats, Inbred F344 | 1986 |
Effect of hypolipidemic drugs gemfibrozil, ciprofibrate, and clofibric acid on peroxisomal beta-oxidation in primary cultures of rainbow trout hepatocytes.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acyl-CoA Oxidase; Animals; Cells, Cultured; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enoyl-CoA Hydratase; Enzyme Activation; Fibric Acids; Gemfibrozil; Hypolipidemic Agents; Isomerases; Liver; Male; Microbodies; Multienzyme Complexes; Oncorhynchus mykiss; Oxidation-Reduction; Oxidoreductases; Peroxisomal Bifunctional Enzyme | 1993 |
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
The effect of peroxisome proliferators on mitochondrial bioenergetics.
Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene | 1999 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplantation; Postoperative Period; Retrospective Studies; Urea | 2000 |
Fibrate treatment can increase serum creatinine levels.
Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Kidney Diseases; Urea | 2001 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipoproteins, LDL; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Retrospective Studies; Treatment Outcome | 2002 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.
Topics: Bezafibrate; Buffers; Clofibric Acid; Electrophoresis, Capillary; Fibric Acids; Gemfibrozil; Hydrogen-Ion Concentration; Hypolipidemic Agents; Pharmaceutical Preparations; Reproducibility of Results; Temperature; Time Factors | 2006 |